Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cyclerion Therapeutics, Inc. - Common Stock (NQ:CYCN)

3.120 +0.030 (+0.97%)
Streaming Delayed Price Updated: 10:17 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cyclerion Therapeutics, Inc. - Common Stock

News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSE - NSA), Urgent.ly, Inc. (OTC Markets - ULYX), UniFirst Corporation (NYSE - UNF)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether SLNO, FORA, MKC, CYCN are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether UNF, CYCN, NSA, ULYX are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSE - NSA), Urgent.ly, Inc. (OTC Markets - ULYX), UniFirst Corporation (NYSE - UNF)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
From Korsana Biosciences, Inc. and Cyclerion Therapeutics, Inc.
Via Business Wire
News headline image
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
Via AB Newswire
News headline image
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat 
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Regina Graul, Ph.D., Promoted to Chief Executive Officer
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Appoints Regina Graul, Ph.D., as President
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Announces Reverse Stock Split
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
Renowned neuroscience leader to further long-term clinical research strategy and external collaborations 
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.